Joining bills already pending before the U.S. House and Senate, the Compounding Clarity Act of 2013 (H.R. 3089) would strengthen the Food and Drug Administration’s (FDA) oversight of drug compounding pharmacies. According to sponsor Rep. H. Morgan Griffith (R-Va.), the bill would protect traditional pharmacies, which would remain under the jurisdiction of state pharmacy boards, while subjecting large-scale compounding entities, “or outsourcing facilities,” to federal requirements. The legislative concerns about compounders follow a deadly nationwide meningitis outbreak traced to contaminated drugs packaged and distributed by large-scale compounder New England Compounding Center. Additional information about pending Senate legislation appears in Issue 61 of this Bulletin. See Rep. H. Morgan Griffith Press Release, September 12, 2013.